Navigation Links
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2011 Results
Date:9/22/2011

CRANBURY, N.J., Sept. 22, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company developing bremelanotide for sexual dysfunction indications and PL-3994 for acute asthma and other indications, today announced results for its fourth quarter and fiscal year ended June 30, 2011.  

Recent Highlights

  • Palatin initiated enrollment in its Phase 2B trial with bremelanotide in premenopausal women with female sexual dysfunction.
  • Palatin announced commencement of a Phase 1 trial of AZD2820, under development for treatment of obesity, in collaboration with AstraZeneca.
  • In March 2011, Palatin closed on a $23.0 million firm commitment public offering consisting of 23 million units at a price to the public of $1.00.  Net proceeds to Palatin after deducting underwriting discounts and other offering expenses were $21.0 million.

  • Fourth Quarter and Fiscal Year End 2011 ResultsPalatin reported a net loss of $3.3 million, or $(0.09) per basic and diluted share, for the quarter ended June 30, 2011, compared to a net loss of $4.2 million, or $(0.40) per basic and diluted share, for the same period in 2010.The change in net loss for the quarter ended June 30, 2011 compared to the net loss for the quarter ended June 30, 2010 was primarily attributable to $1.3 million of non-cash, non-operating income, which represents the decrease in estimated fair value of the warrant liability from March 31, 2011 through May 11, 2011, the date the warrants ceased to be classified as a liability upon stockholder approval of the increase in authorized common stock

    Palatin's net loss for the year ended June 30, 2011 was $12.8 million, or $(0.64) per basic and diluted share, compared to a net loss of $1.8 million, or $(0.18) per basic and diluted share, for the year ended June 30, 2010.  

    The change in net lo
    '/>"/>

    SOURCE Palatin Technologies, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related biology technology :

    1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
    2. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
    3. Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
    4. Palatin Technologies Receives Notification Letter from NYSE Alternext US
    5. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
    6. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
    7. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
    8. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
    9. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
    10. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
    11. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/5/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/4r95kr/clinical ) ... Laboratory, Molecular Diagnostics and Genomic Testing Services Market ... Version" report to their offering. ... molecular diagnostics and pharmacogenics hold the promise of ... is moving out of the national and regional ...
    (Date:5/5/2015)... , May 5, 2015   Tocagen Inc. ... David R. Parkinson , M.D., a venture ... appointed to the board of directors of Tocagen. ... experience in oncology clinical development, including leading clinical ... global approvals of the cancer therapeutics Gleevec®, Femara®, ...
    (Date:5/5/2015)... -- Indianapolis-based medical device manufacturer NICO Corporation is seeing ... including the BrainPath® and Myriad™ technologies offering a ... and then removing affected tissue. More than 1,600 ... institutions throughout the United States ... 12 abstracts, three peer-reviewed publications, and seven presentations ...
    (Date:5/4/2015)... May 4, 2015 Many of us ... for certain infants with rare, inherited mutations of ... consequences of their impaired immune responses. ... identified an important role for calcium signaling in ... tuberculosis, the bacterium causing tuberculosis (TB). ...
    Breaking Biology Technology:European Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market 2015-2019 2Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 2Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 3Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 4NICO Corporation Gains Market Expansion after Multiple Published Clinical Articles Support Access Technology for Deep Brain Lesions 2NICO Corporation Gains Market Expansion after Multiple Published Clinical Articles Support Access Technology for Deep Brain Lesions 3Researchers Discover A Novel And Unexpected Role For Calcium In Controlling Inflammation During Chronic Lung Infection 2Researchers Discover A Novel And Unexpected Role For Calcium In Controlling Inflammation During Chronic Lung Infection 3
    ... Genzyme Corp. said on Wednesday it has agreed ... Wisconsin-Madison biotech spinoff, for $600 million in cash. , ,Bone ... more than $2 billion and almost 7,000 employees worldwide, plan ... companies recently reported healthy quarterly profits and revenues. Bone Care ...
    ... a new copy machine for $57,000. , ,The Z-Corp ... typical office copier: It makes three-dimensional models of small structures ... , ,Using white polymer powder and colored inks, the printer ... a time. Z-Corp is headquartered in Burlington, Massachusetts. , , ...
    ... can submit executive summaries of their businesses for angel ... May 9. , ,The Wisconsin Angel Network ... investor networks with entrepreneurs based on the investors' market ... a deal-flow pipeline, has been designed to be a ...
    Cached Biology Technology:Massachusetts firm to buy UW spinoff Bone Care for $600 million 2Massachusetts firm to buy UW spinoff Bone Care for $600 million 3Start-ups, angels can connect on new state Web site 2Start-ups, angels can connect on new state Web site 3
    (Date:4/20/2015)... 2015 Huntington Memorial Hospital is the first ... new miniaturized, wireless monitoring sensor to manage heart failure ... only FDA-approved heart failure monitoring device that has been ... physicians to manage heart failure. The CardioMEMS ... the pulmonary artery (PA) during a non-surgical procedure to ...
    (Date:4/14/2015)... April 14, 2015  HYPR Corp. today announced ... ® ) Alliance tm , an industry consortium ... commit to share technology and collaborate to deliver ... interoperable, more secure and private, and easier to ... verification that protects sensitive user information and eliminates ...
    (Date:4/13/2015)... 2015  higi, a leading cloud-based consumer engagement platform ... engage with their communities around health and wellness, announced ... secure API.  ... affordable, and convenient vehicle to receive validated health information ... The API will allow higi,s trusted partners, on ...
    Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
    ... industries. They focus light to zap tumors and send digital ... But the physical length of an ordinary laser cannot be ... which limits its application in many industries. Now the Spaser, ... can be as small as needed to fuel nano-technologies of ...
    ... REDWOOD CITY, Calif., Jan. 12, 2011 The ... biocatalysts and services, and secures supply of Codexis ... routes developed by DSM,s InnoSyn™ route scouting services. ... efficient manufacturing processes for active pharmaceutical ingredients and ...
    ... common virus-killing material significantly more effective is a breakthrough from ... Rather than trying to turn the process into profit, ... hope wide adoption will save time, money and perhaps even ... in Environmental Science and Technology , an American Chemical ...
    Cached Biology News:The 'Spaser' heats up laser technology 2DSM and Codexis Sign Enzyme Supply Agreement 2DSM and Codexis Sign Enzyme Supply Agreement 3DSM and Codexis Sign Enzyme Supply Agreement 4Virus killer gets supercharged 2Virus killer gets supercharged 3
    ... The Z-Competent E. coli Transformation Buffer Set ... competent E. coli cells for simple and ... completely eliminates the requirement for heat shocking ... can be performed by adding DNA to ...
    ... The Light Diagnostics Universal Amplicon ... for use in the qualitative ... generated by in vitro ... use only; not to be ...
    Propidium Iodide: {3,8-diamino-5-[3-(diethylmethylammonio)propyl]-6-phenylphenanthridinium diodide}. Antifade Solution: p-Phenylenediamine and glycerol in PBS solution. 2.5ug/mL Propidium Iodide (PI)...
    Apoptosis Detection Systems and Reagents...
    Biology Products: